TELIX Pharmaceuticals Ltd (TLX) — Capital Reinvestment Ratio
TELIX Pharmaceuticals Ltd (TLX) has a Capital Reinvestment Ratio of 0.36x as of June 2025, meaning it reinvests 0% of its operating cash flow (AU$27.98 Million) in capital expenditures (AU$10.13 Million). Check tangible net worth ratio of TELIX Pharmaceuticals Ltd to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
TELIX Pharmaceuticals Ltd Capital Reinvestment Ratio (2020–2024)
This chart tracks TELIX Pharmaceuticals Ltd's Capital Reinvestment Ratio across 3 annual periods. For the full cash flow conversion analysis, see TLX operating cash flow.
Annual Capital Reinvestment Ratio for TELIX Pharmaceuticals Ltd (2020–2024)
Year-by-year Capital Reinvestment Ratio for TELIX Pharmaceuticals Ltd from 2020 to 2024. See TLX free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (AUD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 0.79x | AU$43.03 Million | AU$34.03 Million | ▲ +75.0% |
| 2023 | 0.45x | AU$23.88 Million | AU$10.79 Million | ▲ +175.1% |
| 2020 | 0.16x | AU$1.96 Million | AU$322.00K | — |